1. Home
  2. ARVN vs SUPV Comparison

ARVN vs SUPV Comparison

Compare ARVN & SUPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$6.82

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Logo Grupo Supervielle S.A. each Representing five Class B shares

SUPV

Grupo Supervielle S.A. each Representing five Class B shares

SELL

Current Price

$7.01

Market Cap

703.9M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ARVN
SUPV
Founded
2015
1887
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
703.9M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
ARVN
SUPV
Price
$6.82
$7.01
Analyst Decision
Buy
Hold
Analyst Count
16
5
Target Price
★ $13.93
$11.80
AVG Volume (30 Days)
★ 772.6K
541.9K
Earning Date
11-04-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 58.84
N/A
EPS
★ 1.70
N/A
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$12.76
$32.97
Revenue Next Year
N/A
$20.17
P/E Ratio
$4.04
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.80
$5.83
52 Week High
$14.22
$13.55

Technical Indicators

Market Signals
Indicator
ARVN
SUPV
Relative Strength Index (RSI) 28.59 35.52
Support Level N/A $6.72
Resistance Level $8.52 $7.59
Average True Range (ATR) 0.30 0.28
MACD -0.03 0.03
Stochastic Oscillator 8.61 30.46

Price Performance

Historical Comparison
ARVN
SUPV

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.

Share on Social Networks: